Voyager Lifts Off With $45M From Third Rock Ventures
This article was originally published in The Pink Sheet Daily
Executive Summary
The venture firm’s latest incubated project is a gene therapy start-up targeting CNS disorders. Voyager hopes to have three programs in the clinic by early 2017, targeting Parkinson’s, ALS and Friedreich’s ataxia.